Experimental knee shot aims to slow arthritis damage
NCT ID NCT03706521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small, early-phase study tested a single injection of lorecivivint into the knee joint of 13 people with moderate-to-severe knee osteoarthritis. The goal was to see if the drug could slow cartilage loss, measured by MRI scans. The trial was terminated early, so the results are limited and not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lorecivivint (a drug injected into the knee joint)
- What this could lead to
- If it works, this could point toward a treatment that slows cartilage loss in knee osteoarthritis.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so results are limited and may not apply to a larger population. The drug may not prove effective or safe in the long run.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Carb diet ease knee pain? a study investigates racial differences
- Blocking knee blood vessels may offer new pain relief for severe osteoarthritis
- Which knee implant lasts longer? a Head-to-Head test
- Can cutting carbs curb knee pain? a diet trial puts it to the test
- Can virtual reality make knee pain therapy more engaging?
- Can a stem cell shot rebuild Worn-Out knees?